Eph/ephrin system is an emerging target for cancer therapy but the lack of potent, stable and orally bioavailable compounds is impairing the development of the field. Since 2009 our research group has been devoted to the discovery and development of small molecules targeting Eph/ephrin system and our research culminated with the synthesis of UniPR129, a potent but problematic Eph/ephrin antagonist. Herein, we describe the in vitro pharmacological properties of two derivatives (UniPR139 and UniPR502) stemmed from structure of UniPR129. These two compounds acted as competitive and reversible antagonists of all Eph receptors reducing both ephrin-A1 and -B1 binding to EphAs and EphBs receptors in the low micromolar range. The compounds acted as antagonists inhibiting ephrin-A1-dependent EphA2 activation and UniPR139 exerted an anti-angiogenic effect, inhibiting HUVEC tube formation in vitro and VEGF-induced vessel formation in the chick chorioallantoic membrane assay. Finally, the oral bioavailability of UniPR139 represents a step forward in the search of molecules targeting the Eph/ephrin system and offers a new pharmacological tool useful for future in vivo studies.
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction / Giorgio, Carmine; Incerti, Matteo; Corrado, Miriam; Rusnati, Marco; Chiodelli, Paola; Russo, Simonetta; Callegari, Donatella; Ferlenghi, Francesca; Ballabeni, Vigilio; Barocelli, Elisabetta; Lodola, Alessio; Tognolini, Massimiliano. - In: BIOCHEMICAL PHARMACOLOGY. - ISSN 0006-2952. - 147:(2018), pp. 21-29-29. [10.1016/j.bcp.2017.11.002]